| COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? G Novi, M Mikulska, F Briano, F Toscanini, F Tazza, A Uccelli, M Inglese Multiple sclerosis and related disorders 42, 102120, 2020 | 175 | 2020 |
| Tailoring B cell depletion therapy in MS according to memory B cell monitoring G Novi, F Bovis, S Fabbri, F Tazza, P Gazzola, I Maietta, D Currò, ... Neurology: Neuroimmunology & Neuroinflammation 7 (5), e845, 2020 | 45 | 2020 |
| Predictors of ocrelizumab effectiveness in patients with multiple sclerosis M Cellerino, G Boffa, C Lapucci, F Tazza, E Sbragia, E Mancuso, ... Neurotherapeutics 18 (4), 2579-2588, 2021 | 34 | 2021 |
| Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? F Tazza, C Lapucci, M Cellerino, G Boffa, G Novi, I Poire, E Mancuso, ... Journal of the Neurological Sciences 427, 117501, 2021 | 18 | 2021 |
| Case Report: Post-COVID-19 Vaccine Recurrence of Guillain–Barré Syndrome Following an Antecedent Parainfectious COVID-19–Related GBS M Bellucci, F Germano, S Grisanti, C Castellano, F Tazza, EM Mobilia, ... Frontiers in Immunology 13, 894872, 2022 | 16 | 2022 |
| Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study VD Boccia, C Lapucci, M Cellerino, F Tazza, A Rossi, S Schiavi, ... Multiple Sclerosis Journal 29 (3), 475-478, 2023 | 6 | 2023 |
| Mapping tissue microstructure across the human brain on a clinical scanner with soma and neurite density image metrics S Schiavi, M Palombo, D Zacà, F Tazza, C Lapucci, L Castellan, ... Human Brain Mapping 44 (13), 4792-4811, 2023 | 5 | 2023 |
| Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities C Lapucci, F Tazza, S Rebella, G Boffa, E Sbragia, N Bruschi, E Mancuso, ... Frontiers in Neurology 14, 1084661, 2023 | 4 | 2023 |
| CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis I Schiavetti, L Barcellini, C Lapucci, F Tazza, M Cellerino, E Capello, ... Multiple Sclerosis and Related Disorders 70, 104494, 2023 | 4 | 2023 |
| Dissecting brain grey and white matter microstructure: a novel clinical diffusion MRI protocol S Schiavi, M Palombo, D Zacà, F Tazza, C Lapucci, L Castellan, ... bioRxiv, 2022.04. 08.487640, 2022 | 3 | 2022 |
| The role of RIM lesions in predicting longitudinal brain and retinal atrophy M Cellerino, F Tazza, S Schiavi, C Pierella, T Sirito, D Boccia, E Mancuso, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 795-796, 2022 | 2 | 2022 |
| CD19+ B cell numbers predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis I Schiavetti, L Barcellini, C Lapucci, F Tazza, M Cellerino, E Capello, ... MedrXiv, 2022.07. 02.22277178, 2022 | 2 | 2022 |
| Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center prospective observational study M Cellerino, E Mancuso, G Boffa, N Bruschi, F Tazza, G Novi, A Uccelli, ... Multiple Sclerosis Journal 27 (2_ SUPPL), 501-502, 2021 | 2 | 2021 |
| Multiparametric Characterization and Spatial Distribution of Different MS Lesion Phenotypes F Tazza, G Boffa, S Schiavi, C Lapucci, GF Piredda, E Cipriano, D Zacà, ... American Journal of Neuroradiology, 2024 | 1 | 2024 |
| Clinical and radiological correlates of apathy in multiple sclerosis F Tazza, S Schiavi, E Leveraro, M Cellerino, G Boffa, S Ballerini, ... Multiple Sclerosis Journal 30 (2), 247-256, 2024 | 1 | 2024 |
| In-vivo characterization of macro-and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis M Cellerino, S Schiavi, C Lapucci, E Sbragia, G Boffa, C Rolla-Bigliani, ... Frontiers in Neuroscience 17, 1112199, 2023 | 1 | 2023 |
| Longitudinal assessment of balance impairment in multiple sclerosis identify patients with silent disease progression E Mancuso, G Boffa, D Boccia, F Tazza, C Lapucci, E Sbragia, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 198-199, 2022 | 1 | 2022 |
| Ocrelizumab treatment in patients with progressive multiple sclerosis: a single-center real-world experience (2504) M Cellerino, G Boffa, C Lapucci, E Sbragia, N Bruschi, E Mancuso, ... Neurology 96 (15_supplement), 2504, 2021 | 1 | 2021 |
| Short-term evaluation of alemtuzumab to ocrelizumab switch in ms patients with disease activity after alemtuzumab: an italian multicentric study C Lapucci, J Frau, E Cocco, P Cavalla, M Vercellino, M Petracca, ... MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 195-196, 2020 | 1 | 2020 |
| Short-term safety and efficacy of switching from alemtuzumab to ocrelizumab in MS patients with disease activity after two alemtuzumab courses: an Italian multicentric, real … C Lapucci, J Frau, E Cocco, M Vercellino, P Cavalla, M Petracca, ... EUROPEAN JOURNAL OF NEUROLOGY 27, 929-929, 2020 | 1 | 2020 |
